Under construction – not a live service
Sign in
Taking people in CanadaPhase 1

Long-term safety follow-up of people previously given INV-347 for obesity

Checks safety of INV-347 in adults with obesity who took it in an earlier study.

Plain-language title generated from the registry record
Registry title: Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108

Key facts

Where
Québec, CanadaSee the site
Phase
Phase 1

Where in Canada

  • Syneos Health CliniqueQuébec, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Novo Nordisk A/S
Trial code
NCT07153172
Record updated
6 March 2026
Original description
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.Read full original descriptionShow less

Safety Follow-up Study of Participants Previously Dosed With INV-347 in the First-in-Human Study INV-CL-108

The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this study as it looks into the safety of a drug previously dosed. The study will last until visit 21.

Inclusion: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study; Male or female (sex at birth); Age 18 years or above at the time of signing the informed consent; Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment [above lower limit of qualification (LLOQ) of 0.5 nanogram per milliliter (ng/mL)].

Exclusion: The study has no exclusion criteria.

ClinicalTrials.gov NCT07153172